375 results on '"Xicoy B"'
Search Results
2. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria
3. Quantification of histone H1 subtypes using targeted proteomics
4. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
5. The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
6. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?
7. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
8. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
9. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
10. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPACT OF GERIATRIC ASSESSMENT AND SOMATIC MUTATIONS IN HIGH-RISK MYELODYSPLASTIC SYNDROMES NOT ELIGIBLE FOR ALO-HCST. CET-AZA-2016–1 2022 UPDATE. ON BEHALF OF THE CETLAM GROUP
11. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
12. Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
13. Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): CLINICO-BIOLOGICAL CHARACTERISTICS AND OUTCOME OF 313 CHRONIC MYELOMONOCYTIC LEUKEMIA PATIENTS INCLUDING 104 FORMERLY REFERRED TO AS OLIGOMONOCYTIC
14. P135 - Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
15. P120 - Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): CLINICO-BIOLOGICAL CHARACTERISTICS AND OUTCOME OF 313 CHRONIC MYELOMONOCYTIC LEUKEMIA PATIENTS INCLUDING 104 FORMERLY REFERRED TO AS OLIGOMONOCYTIC
16. P118 - Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
17. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
18. P086 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPACT OF GERIATRIC ASSESSMENT AND SOMATIC MUTATIONS IN HIGH-RISK MYELODYSPLASTIC SYNDROMES NOT ELIGIBLE FOR ALO-HCST. CET-AZA-2016–1 2022 UPDATE. ON BEHALF OF THE CETLAM GROUP
19. P045 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?
20. P052 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
21. P041 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
22. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
23. Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients
24. Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study
25. P690: GENE MUTATIONAL PROFILE ASSOCIATED WITH TREATMENT FAILURE OR PROGRESSION IN CHRONIC MYELOID LEUKEMIA
26. P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.
27. P728: GENE EXPRESSION PROFILE REVELS T-LYMPHOCYTES ACTIVATION THROUGH CELL CYCLE PROGRESSION AND MITOCHONDRIAL METABOLISM REGULATION IN MYELODYSPLASTIC SYNDROMES WITH DEL(5Q) AFTER LENALIDOMIDE TREATMENT
28. Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (Bone Marrow Transplantation, (2022), 57, 3, (416-422), 10.1038/s41409-021-01553-x)
29. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
30. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (vol 57, pg 416, 2022)
31. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
32. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
33. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
34. Toxic iron species in lower-risk myelodysplastic syndrome patients : course of disease and effects on outcome
35. Topic: AS02-Epidemiology
36. STUDY OF THE MECHANISMS OF THROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS
37. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
38. Table 1. Clinical-biological and molecular characteristics of CML patients in each group evaluated
39. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
40. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
41. ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL
42. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
43. COMPARISON OF LEVOFLOXACIN PROPHYLAXIS VERSUS NO PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. RETROSPECTIVE COHORT STUDY FROM A SINGLE CENTER: PH-P465
44. Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients
45. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model: Prognostication in myelofibrosis
46. Impact of previous admission to an intensive care unit on stem cell transplantation outcome
47. Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema
48. Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies
49. CYTOGENETIC CHARACTERIZATION OF CHRONIC MYELOID LEUKEMIA AND ITS PROGNOSTIC IMPACT UPON TREATMENT WITH TYROSINE KINASE INHIBITORS
50. EXPERIENCE WITH ETANERCEPT IN THE TREATMENT OF ACUTE GLUCOCORTICOID-RESISTANT GRAFT-VERSUS-HOST DISEASE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.